Please login to the form below

Not currently logged in
Email:
Password:

Biogen Idec's haemophilia candidate faces US delay

FDA extends review of Alprolix

Biogen Idec 

Biogen Idec will have to wait a little longer before it can get the FDA's verdict on its new haemophilia B therapy Alprolix.

The US regulator has extended its review period by three months for the long-lasting recombinant factor IX Fc fusion protein candidate, which is one of two haemophilia products licensed by Biogen Idec from Swedish Orphan Biovitrum (Sobi).

Biogen Idec said it has already provided the FDA with additional information related to the validation of a manufacturing step for Alprolix, and the agency will use the additional time to review this data.

With Alprolix for haemophilia B and its long-acting Factor VIII candidate Eloctate for haemophilia A - which was filed for approval in the US in January - Biogen Idec is hoping to challenge a market shared largely between Baxter, Pfizer and Bayer.  

Both Eloctate and Alprolix make use of Fc fusion technology, which extends the half-life of the drug in the body and allows treatments to be dosed less frequently than current therapies. Biogen Idec is the first company to use this technology in heamophilia.

The established players in haemophilia are also developing long-acting variants of their products, but Biogen Idec is around a year in front and could make rapid inroads into the market.

At the moment the leading haemophilia A treatment is Baxter's Advate, with Pfizer's BeneFix leading the haemophilia B category, but the market looks set to get increasingly crowded.

Baxter launched an assault on the haemophilia B sector with the approval of Rixubis in the US in June, while Novo Nordisk and CSL Behring also have long-acting drugs in phase III testing.

Analysts have suggested Biogen Idec's haemophilia franchise could reach $1bn a year fairly quickly, even though it only has rights to the drugs in North America at the moment, with Sobi retaining ownership in Europe.

Alprolix is also under review by regulatory authorities in a number of countries, including Canada, Australia and Japan.

This article was correct on December 9, 2013, to clarify that Fc fusion technology did not belong to Sobi.

Article by
Phil Taylor

3rd December 2013

From: Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....

Infographics